Cargando…

A model of human lung fibrogenesis for the assessment of anti-fibrotic strategies in idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease with limited therapeutic options. K(Ca)3.1 ion channels play a critical role in TGFβ1-dependent pro-fibrotic responses in human lung myofibroblasts. We aimed to develop a human lung parenchymal model of fibrogenesis and t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roach, Katy M., Sutcliffe, Amanda, Matthews, Laura, Elliott, Gill, Newby, Chris, Amrani, Yassine, Bradding, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762721/ https://www.ncbi.nlm.nih.gov/pubmed/29321510 http://dx.doi.org/10.1038/s41598-017-18555-9

Ejemplares similares

Increased constitutive αSMA and Smad2/3 expression in idiopathic pulmonary fibrosis myofibroblasts is K(Ca)3.1-dependent
por: Roach, Katy M, et al.
Publicado: (2014)

The K(+) Channel K(Ca)3.1 as a Novel Target for Idiopathic Pulmonary Fibrosis
por: Roach, Katy Morgan, et al.
Publicado: (2013)

Lipoxin A(4) Attenuates Constitutive and TGF-β1–Dependent Profibrotic Activity in Human Lung Myofibroblasts
por: Roach, Katy M., et al.
Publicado: (2015)

Correction: The K(+) Channel K(Ca)3.1 as a Novel Target for Idiopathic Pulmonary Fibrosis
por: Roach, Katy M, et al.
Publicado: (2014)

Tensin1 expression and function in chronic obstructive pulmonary disease
por: Stylianou, Panayiota, et al.
Publicado: (2019)

Human lung myofibroblast TGFβ1-dependent Smad2/3 signalling is Ca(2+)-dependent and regulated by K(Ca)3.1 K(+) channels
por: Roach, Katy M, et al.
Publicado: (2015)

Evaluation of Pirfenidone and Nintedanib in a Human Lung Model of Fibrogenesis
por: Roach, KM, et al.
Publicado: (2021)

Disease progression in idiopathic pulmonary fibrosis under anti-fibrotic treatment
por: Cilli, Aykut, et al.
Publicado: (2023)

FoxO3 an important player in fibrogenesis and therapeutic target for idiopathic pulmonary fibrosis
por: Al‐Tamari, Hamza M, et al.
Publicado: (2017)

Cost-effectiveness of the anti-fibrotics for the treatment of idiopathic pulmonary fibrosis in the United States
por: Dempsey, Timothy M., et al.
Publicado: (2022)

Anti-fibrotic therapy and lung transplant outcomes in patients with idiopathic pulmonary fibrosis
por: Astor, Todd L., et al.
Publicado: (2023)

Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review
por: Khor, Yet H., et al.
Publicado: (2020)

Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis
por: Collins, Bridget F., et al.
Publicado: (2019)

Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
por: Hostettler, Katrin E, et al.
Publicado: (2014)

Pulmonary vascular volume is associated with DLCO and fibrotic score in idiopathic pulmonary fibrosis: an observational study
por: Wu, Wen-Jui, et al.
Publicado: (2022)

Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments
por: De Biasi, Sara, et al.
Publicado: (2015)

A Review of Pirfenidone as an Anti-Fibrotic in Idiopathic Pulmonary Fibrosis and Its Probable Role in Other Diseases
por: Shah, Parth V, et al.
Publicado: (2021)

Human Lung Mast Cells Impair Corticosteroid Responsiveness in Human Airway Smooth Muscle Cells
por: Alzahrani, Abdulrahman, et al.
Publicado: (2021)

Changes in patient-reported outcomes in patients with non-idiopathic pulmonary fibrosis fibrotic interstitial lung disease and progressive pulmonary fibrosis
por: Takei, Reoto, et al.
Publicado: (2023)

Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis
por: Yoshikawa, Takumi, et al.
Publicado: (2020)

Anti-Fibrotic Efficacy of Apigenin in a Mice Model of Carbon Tetrachloride-Induced Hepatic Fibrosis by Modulation of Oxidative Stress, Inflammation, and Fibrogenesis: A Preclinical Study
por: Melaibari, Maryam, et al.
Publicado: (2023)

Correction to: Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis
por: Yoshikawa, Takumi, et al.
Publicado: (2020)

Cluster phenotypes in a non-idiopathic pulmonary fibrosis fibrotic interstitial lung diseases cohort in Singapore
por: Kam, Michelle Li Wei, et al.
Publicado: (2022)

Hypoxia Inducible Factor 1A Supports a Pro-Fibrotic Phenotype Loop in Idiopathic Pulmonary Fibrosis
por: Epstein Shochet, Gali, et al.
Publicado: (2021)

Antigen avoidance and environmental inhalation challenge for successful diagnosis of fibrotic hypersensitivity pneumonitis mimicking idiopathic pulmonary fibrosis
por: Ito, Yasuhiro, et al.
Publicado: (2022)

Bronchoalveolar Lavage Cell Count and Lymphocytosis Are the Important Discriminators between Fibrotic Hypersensitivity Pneumonitis and Idiopathic Pulmonary Fibrosis
por: Sobiecka, Małgorzata, et al.
Publicado: (2023)

The In Vivo Fibrotic Role of FIZZ1 in Pulmonary Fibrosis
por: Liu, Tianju, et al.
Publicado: (2014)

Usefulness of FAPα assessment in bronchoalveolar lavage as a marker of fibrogenesis: results of a preclinical study and first report in patients with idiopathic pulmonary fibrosis
por: Lavis, Philomène, et al.
Publicado: (2023)

Fibrogenesis
por: Harington, J. S.
Publicado: (1974)

Fibrogenesis
por: Munger, John S., et al.
Publicado: (2010)

The clinical impact of comorbidities among patients with idiopathic pulmonary fibrosis undergoing anti-fibrotic treatment: A multicenter retrospective observational study
por: Aoki, Ayako, et al.
Publicado: (2023)

Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients
por: Feng, Haoshen, et al.
Publicado: (2020)

Neutrophils Modulate Fibrogenesis in Chronic Pulmonary Diseases
por: Ding, Lili, et al.
Publicado: (2021)

Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity
por: Sato, Seidai, et al.
Publicado: (2017)

Medium-long term prognosis prediction for idiopathic pulmonary fibrosis patients based on quantitative analysis of fibrotic lung volume
por: Du, Kaifeng, et al.
Publicado: (2022)

Uridine supplementation exerts anti-inflammatory and anti-fibrotic effects in an animal model of pulmonary fibrosis
por: Cicko, Sanja, et al.
Publicado: (2015)

The Anti-fibrotic Effects and Mechanisms of MicroRNA-486-5p in Pulmonary Fibrosis
por: Ji, Xiaoming, et al.
Publicado: (2015)

The Interaction Between Pulmonary Fibrosis and COVID-19 and the Application of Related Anti-Fibrotic Drugs
por: Shen, Hao, et al.
Publicado: (2022)

Anti-fibrotic Treatment for Pulmonary Fibrosis Induced by COVID-19: A Case Presentation
por: Sakızcı Uyar, Bahar, et al.
Publicado: (2022)

Mechanical induction of cough in Idiopathic Pulmonary Fibrosis
por: Jones, Richard M, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_apnolhutopcqdcsg2qava77kqk